• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康等效年与质量调整生命年:追求进步

Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress.

作者信息

Mehrez A, Gafni A

机构信息

Department of Industrial Engineering and Management, Ben Gurion University of the Negev, Beer Sheva, Israel.

出版信息

Med Decis Making. 1993 Oct-Dec;13(4):287-92. doi: 10.1177/0272989X9301300404.

DOI:10.1177/0272989X9301300404
PMID:8246700
Abstract

The authors respond to the contention that healthy-years equivalents (HYEs) do not fulfil claims they previously made. They refute the argument for the equivalence of the two-stage lottery and the time tradeoff and show that it fails to recognize the difference between choice problems under uncertainty versus certainty. They also dismiss the claim that HYEs assume risk neutrality with respect to healthy years of life, and show that HYEs are superior to the "general" (risk-averse) form of QALYs because HYEs employ fewer assumptions; in particular, they do not assume a specific form of the individual's utility function. The examples they used earlier are demonstrated to be conclusive, and the authors respond to arguments about the practical aspects of using HYEs vs QALYs. Finally, they take issue with the assumption that the roots of the QALY model are all attributable to utility theory.

摘要

作者们回应了关于健康年当量(HYEs)未能实现其先前主张的论点。他们驳斥了两阶段彩票与时间权衡等价的观点,并表明该观点未能认识到不确定性与确定性下选择问题之间的差异。他们还驳回了关于HYEs在健康寿命年方面假定风险中性的说法,并表明HYEs优于QALYs的“一般”(风险厌恶)形式,因为HYEs采用的假设更少;特别是,它们不假定个体效用函数的特定形式。他们早期使用的例子被证明是有说服力的,作者们回应了关于使用HYEs与QALYs的实际方面的论点。最后,他们对QALY模型的根源都可归因于效用理论这一假设提出了质疑。

相似文献

1
Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress.健康等效年与质量调整生命年:追求进步
Med Decis Making. 1993 Oct-Dec;13(4):287-92. doi: 10.1177/0272989X9301300404.
2
Are healthy-years equivalents an improvement over quality-adjusted life years?健康年当量相对于质量调整生命年来说是一种改进吗?
Med Decis Making. 1993 Oct-Dec;13(4):281-6. doi: 10.1177/0272989X9301300403.
3
The ranking properties of healthy-years equivalents and quality-adjusted life-years under certainty and uncertainty.健康年当量和质量调整生命年在确定性和不确定性条件下的排序属性。
Int J Technol Assess Health Care. 1995 Winter;11(1):40-8. doi: 10.1017/s0266462300005249.
4
QALYs, HYEs and individual preferences--a graphical illustration.
Soc Sci Med. 1994 Dec;39(12):1623-32. doi: 10.1016/0277-9536(94)90076-0.
5
Economics, health and health economics: HYEs (healthy-years equivalent) versus QALYs (quality-adjusted live-year).经济学、健康与健康经济学:健康等效年(HYEs)与质量调整生命年(QALYs)
J Health Econ. 1993 Oct;12(3):325-39. doi: 10.1016/0167-6296(93)90015-7.
6
QALYs (quality-adjusted life-years) versus HYEs (healthy years equivalents).质量调整生命年(QALYs)与健康等效年(HYEs)的比较
J Health Econ. 1993 Oct;12(3):311-23. doi: 10.1016/0167-6296(93)90014-6.
7
QALYs and HYEs (healthy year equivalents): under what conditions are they equivalent?质量调整生命年与健康等效年:在何种条件下它们是等效的?
J Health Econ. 1995 May;14(1):17-37. doi: 10.1016/0167-6296(94)00033-z.
8
QALYs versus HYEs--what's right and what's wrong. A review of the controversy.质量调整生命年与健康效用指数——何为正确,何为错误。争议综述。
J Health Econ. 1998 Oct;17(5):607-25. doi: 10.1016/s0167-6296(97)00037-4.
9
Incorporating feelings related to the uncertainty about future health in utility measurement.在效用测量中纳入与未来健康不确定性相关的感受。
Health Econ. 2008 Oct;17(10):1207-13. doi: 10.1002/hec.1320.
10
Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs).药物干预经济评估中基于偏好的结局指标:质量调整生命年(QALYs)与健康年当量(HYEs)。
Pharmacoeconomics. 1992 May;1(5):338-45. doi: 10.2165/00019053-199201050-00005.

引用本文的文献

1
Quality-adjusted life years in macular oedema due to age-related macular degeneration, diabetes and central retinal vein occlusion: the impact of anti-VEGF agents in a tertiary centre in Greece.与年龄相关的黄斑变性、糖尿病和视网膜中央静脉阻塞导致的黄斑水肿的质量调整生命年:希腊一家三级中心抗血管内皮生长因子药物的影响。
Int Ophthalmol. 2022 Sep;42(9):2673-2684. doi: 10.1007/s10792-022-02256-y. Epub 2022 Apr 13.
2
International comparison of comparative effectiveness research in five jurisdictions: insights for the US.五个司法管辖区的比较有效性研究的国际比较:对美国的启示。
Pharmacoeconomics. 2010;28(10):813-30. doi: 10.2165/11536150-000000000-00000.
3
Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.
药物预期和非预期效应的联合评估:以用于新生血管性年龄相关性黄斑变性的血管内皮生长因子抑制剂为例
J Ophthalmol. 2009;2009:540431. doi: 10.1155/2009/540431. Epub 2010 Feb 16.
4
Obtaining utility estimates of the health value of commonly prescribed treatments for asthma and depression.获取哮喘和抑郁症常用处方治疗的健康价值效用估计值。
Med Decis Making. 2008 Sep-Oct;28(5):732-50. doi: 10.1177/0272989X08315251. Epub 2008 Aug 25.
5
The economic burden of coronary heart disease in the UK.英国冠心病的经济负担。
Heart. 2002 Dec;88(6):597-603. doi: 10.1136/heart.88.6.597.
6
Health profile preferences of hepatitis C patients.丙型肝炎患者的健康状况偏好
Dig Dis Sci. 2000 Feb;45(2):345-50. doi: 10.1023/a:1005420828332.
7
Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.成本效益、质量调整生命年与支持性护理。重组人促红细胞生成素治疗癌症相关性贫血。
Pharmacoeconomics. 1999 Nov;16(5 Pt 1):459-72. doi: 10.2165/00019053-199916050-00004.
8
Benefit valuation in economic evaluation of cancer therapies. A systematic review of the published literature.癌症治疗经济评估中的效益估值:已发表文献的系统综述
Pharmacoeconomics. 1999 Jul;16(1):17-31. doi: 10.2165/00019053-199916010-00003.
9
Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.加拿大药品经济评估指南。加拿大药物经济学协作研讨会。
Pharmacoeconomics. 1996 Jun;9(6):535-59. doi: 10.2165/00019053-199609060-00008.
10
Guidelines for pharmacoeconomic studies. The ways forward.药物经济学研究指南。前进的道路。
Pharmacoeconomics. 1994 Dec;6(6):493-7. doi: 10.2165/00019053-199406060-00002.